Search research articles
Contact Us
Filters
Showing results (201-210 of 289) with videos related to
Page
of 29
Sort By:
Therapeutic Advances in Medical Oncology
|
November 16, 2020
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study
Giuseppe Procopio, Vincenzo Emanuele Chiuri, Monica Giordano, et al.
Cancer Medicine
|
March 21, 2022
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study
Giandomenico Roviello, Elisabetta Gambale, Roberta Giorgione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2023
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, et al.
Frontiers in Oncology
|
June 25, 2021
Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
Marco Stellato, Daniele Santini, Elena Verzoni, et al.
Future Oncology (London, England)
|
October 6, 2015
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients
Vincenza Conteduca, Orazio Caffo, Lucia Fratino, et al.
Oncotarget
|
December 17, 2017
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis
Daniele Santini, Raffaele Ratta, Francesco Pantano, et al.
Clinical Genitourinary Cancer
|
April 17, 2024
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Journal of Clinical Medicine
|
June 26, 2020
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
Vincenza Conteduca, Orazio Caffo, Emanuela Scarpi, et al.
Urologic Oncology
|
May 20, 2015
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation
Daniele Raggi, Luigi Mariani, Patrizia Giannatempo, et al.
Lancet (London, England)
|
September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
Sumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.
Page
of 29
Search research articles
Search
Showing results (201-210 of 289) with videos related to
Sort By:
Page
of 29
Therapeutic Advances in Medical Oncology
|
November 16, 2020
Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study
Giuseppe Procopio, Vincenzo Emanuele Chiuri, Monica Giordano, et al.
Cancer Medicine
|
March 21, 2022
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study
Giandomenico Roviello, Elisabetta Gambale, Roberta Giorgione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2023
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, et al.
Frontiers in Oncology
|
June 25, 2021
Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
Marco Stellato, Daniele Santini, Elena Verzoni, et al.
Future Oncology (London, England)
|
October 6, 2015
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients
Vincenza Conteduca, Orazio Caffo, Lucia Fratino, et al.
Oncotarget
|
December 17, 2017
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis
Daniele Santini, Raffaele Ratta, Francesco Pantano, et al.
Clinical Genitourinary Cancer
|
April 17, 2024
Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27
Marco Stellato, Sebastiano Buti, Marco Maruzzo, et al.
Journal of Clinical Medicine
|
June 26, 2020
Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy
Vincenza Conteduca, Orazio Caffo, Emanuela Scarpi, et al.
Urologic Oncology
|
May 20, 2015
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation
Daniele Raggi, Luigi Mariani, Patrizia Giannatempo, et al.
Lancet (London, England)
|
September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
Sumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.
Page
of 29